SavedAdd your journal

Journals / ANKEM Dergisi / 2016 / Cilt: 30 - Sayı: 1

Results of Boceprevir and Telaprevir Combination Therapy in Chronic Hepatitis C Patients in Nevşehir Province

NEVŞEHİR İLİNDE KRONİK HEPATİT C HASTALARINDA BOCEPREVİR VE TELAPREVİR KOMBİNASYON TEDAVİSİ SONUÇLARI

Deniz BORCAK
Ünal ÇAĞIR
Pages
12–17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although adverse effects were frequently observed, the discontinuation rate of combination therapy was low.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Chronic Hepatitis C infection is an important health problem in Turkey.
📊
Key Findings & Data:The most frequently observed hepatitis C virus (HCV) genotype in Turkey is genotype 1b.
💡
Conclusion & Impact:Although adverse effects were frequently observed, the discontinuation rate of combination therapy was low.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Chronic Hepatitis C infection is an important health problem in Turkey. The most frequently observed hepatitis C virus (HCV) genotype in Turkey is genotype 1b. Protease inhibitor antiviral agents boceprevir (BOC) and telaprevir (TVR) for HCV infection are one of the major advances in its medical treatment. The combination of BOC and TVR with pegylated interferon- alpha and ribavirin (PegIFN/RBV) for the treatment of patients infected with HCV genotype 1 has caused significantly inc- reased rates of sustained virologic response (SVR). In this study, we aimed to evaluate the efficacy and adverse effects of BOC and TVR with PegIFN/RBV for the retreatment of patients infected with HCV genotype 1 who have compensated liver dise- ase and who have previously received PegIFN/RBV therapy but could not achieve SVR. Sustained virologic response was achieved in 14 (63.6 %) of the 22 patients. The most observed adverse effects were anaemia, dry skin, nausea, fatigue at TVR group and fatigue, dry skin, nausea, anaemia and neutropenia at BOC group. Sustained virologic response rates were high with the combination of BOC and TVR with PegIFN/RBV. Although adverse effects were frequently observed, the discontinuation rate of combination therapy was low.

Özet

Kronik hepatit C infeksiyonu Türkiye’de önemli bir sağlık sorunudur. Türkiye’de en sık görülen hepatitis C virüs (HCV) genotipi 1b’dir. Hepatit C tedavisinde önemli gelişmelerden biri proteaz inhibitörleri boceprevir (BOC) ve telaprevirin (TVR) kullanıma girmesidir. Hepatit C genotip 1 ile infekte hastalarda pegile interferon-alfa ve ribavirin (PegIFN/RBV) ile beraber BOC ve TVR kullanımı kalıcı virolojik cevap (KVC) oranlarını belirgin olarak artırmıştır. Bu çalışmada kompanse karaciğer hastalığı olan HCV genotip 1 ile infekte, daha önce PegIFN/RBV tedavisi almış ama KVC elde edilememiş hastalar- da yeniden tedavide PegIFN/RBV kombinasyonuna eklenen BOC ve TVR etkinliği ve yan etkileri değerlendirmek amaçlan- mıştır. Toplam 22 hastanın 14’ünde (% 63.6) KVC elde edilmiştir. BOC grubunda en sık gözlenen yan etkiler halsizlik, kuru cilt, bulantı, anemi, nötropeni ve TVR grubunda ise anemi, kuru cilt, bulantı ve halsizlik olmuştur. PegIFN/RBV ile beraber BOC ve TVR kullanımı ile KVC yüksek oranda saptanmıştır. Yan etkilerin sıklığına rağmen kombinasyon tedavisinin kesilme oranı düşük olmuştur.

🔖

Cite This Article

BORCAK, D., ÇAĞIR, Ü. (2016). Results of Boceprevir and Telaprevir Combination Therapy in Chronic Hepatitis C Patients in Nevşehir Province. ANKEM Dergisi, Cilt: 30 - Sayı: 1, 12–17. https://ajindex.com/articles/219359

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Aygen B, Yıldız O, Akhan S, Çelen MK ve ark. Retreatment of chronic hepatitis C infection with telaprevir: preliminary results in Turkey, Balkan Med J 2015;32(3):266-72.
  2. Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection (HCV RESPOND-2 trial), N Engl J Med 2011;364(13):1207-17.
  3. Bertino G, Ardiri A, Proiti M et al. Chronic hepati- tis C: this and the new era of treatment, World J Hepatol 2016;8(2):92-106.
  4. Borcak D, Çağır Ü, Yalçıner A. Nevşehir ilinde hepatit C virus genotip dağılımı ile serum alanin aminotransferaz ve kantitatif serum HCV RNA düzeyleri ilişkisi, ANKEM Derg 2015;29(1):36-40
  5. Bozdayi AM, Aslan N, Bozdayi G et al. Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients, Arch Virol 2004;149:2115-29.
  6. Cooper C, Lester R, Thorlund K et al. Direct- acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta- analysis, QJM 2013;106(2):153-63.
  7. Cooper C, Druyts E, Thorlund K et al. Boceprevir and telaprevir for the treatment of chronic hepati- tis C genotype 1 infection: an indirect comparison meta-analysis, Ther Clin Risk Manag 2012;8:105- 30
  8. Cunningham M, Foster GR. Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection, Therap Adv Gastroenterol 2012;5(2):139- 51.
  9. Çakaloğlu Y. Kronik C hepatitis tedavisi 2012, direk etkili antiviral ajanlarla sağlananlar, ANKEM Derg 2012;26(Ek 2):135-43
  10. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection, J Hepatol 2014;60:392- 420.
  11. European Association for the Study of the Liver. Recommendations on treatment of hepatitis C 2015, J Hepatol 2015;63:199-236.
  12. Ghany MG, Nelson DR, Strader DB et al. An update on treatment of genotype 1 chronic hepati- tis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases, Hepatol 2011;54(4):1433-44.
  13. González-Grande R, Jiménez-Pérez M, González Arjona C, Mostazo Torres J. New approaches in the treatment of